Meadow Creek Investment Management LLC boosted its position in Bioverativ Inc (NASDAQ:BIVV) by 27.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 10,670 shares of the biotechnology company’s stock after purchasing an additional 2,288 shares during the period. Meadow Creek Investment Management LLC’s holdings in Bioverativ were worth $575,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of BIVV. Robeco Institutional Asset Management B.V. bought a new stake in Bioverativ in the 4th quarter worth about $105,000. American Assets Investment Management LLC bought a new stake in Bioverativ in the 4th quarter worth about $108,000. Advisors Asset Management Inc. bought a new stake in Bioverativ in the 3rd quarter worth about $137,000. Ladenburg Thalmann Financial Services Inc. purchased a new position in Bioverativ in the third quarter valued at about $190,000. Finally, Bailard Inc. purchased a new position in Bioverativ in the fourth quarter valued at about $216,000. 97.18% of the stock is owned by institutional investors and hedge funds.
BIVV has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 target price on the stock in a research note on Monday, January 8th. William Blair reiterated a “hold” rating on shares of Bioverativ in a research note on Thursday, March 8th. Royal Bank of Canada boosted their target price on shares of Bioverativ to $68.00 and gave the company a “market perform” rating in a research note on Thursday, January 18th. Jefferies Group boosted their target price on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a research note on Thursday, January 18th. Finally, Raymond James Financial cut shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. Twelve equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $63.83.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.01. The company had revenue of $328.70 million for the quarter, compared to analysts’ expectations of $325.89 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. analysts forecast that Bioverativ Inc will post 3.82 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3299743/bioverativ-inc-bivv-holdings-raised-by-meadow-creek-investment-management-llc.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.